Abstract
ObjectiveThe use of glucagon-like peptide 1 receptor agonists has been associated with gastroparesis, but little is known about the risk of gastroparesis in those with obesity but without type 2...
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have